Screening new agents and developing new methods for treating multi-drug resistant pathogens effectively.
Antibiotics have highly increased human life expectancy. However, multidrug-resistance has become a common problem and conventional antibiotics are becoming increasingly ineffective owing to their unbridled use. Although medicine urgently requires new drugs, hardly any new agent candidates are being developed, as the quest for new substances is economically unattractive for pharmaceutical companies.
DZIF scientists in the research area “Novel Antibiotics” intend to bridge the gap between basic research and current drug development activities in the industry. They are involved in screening new agents and developing methods for treating multidrug-resistant pathogens effectively.
DZIF scientists have already brought several new agents into preclinical development. Examples are corallopyronin A for worm infections and aminochelocardins for urinary tract infection.
Compound Resources and Medicinal Chemistry
The DZIF makes available an extensive collection of substances; medicinal chemistry is used to advance significant agent candidates.